Linaclotide for treating patients with irritable bowel syndrome with predominant constipation: a multicentre study of real-world data in China

Abstract

Introduction: Linaclotide, a guanylate cyclase C agonist that improves the symptoms of irritable bowel syndrome with predominant constipation (IBS-C), has been recently approved for IBS-C treatment. This study aimed to report real-world data on linaclotide treatment in China. Methods: This was a prospective multicentre study of the effectiveness of linaclotide treatment in patients with IBS-C from 10 primary medical institutions. Changes in defecation, abdominal symptoms, the IBS symptom severity scale (IBS-SSS), IBS quality of life questionnaire (IBS-QOL), Zung Self-Rating Anxiety Scale and Self-Rating Depression Scale in patients were evaluated to determine the drug’s clinical efficacy and safety. Results: We enrolled 97 patients (mean age: 52.39 ± 13.99 years), 55 of whom were women (56.7%). In terms of efficacy, the number of the patients’ defecation per week and Bristol stool form scale scores significantly increased at week 4 and week 12 compared with the values at the baseline. The baseline average IBS-SSS score was 211.01 ± 81.23. Of the patients, 24 had severe IBS-C, and their IBS-SSS scores at week 4 (51.81 ± 54.42) and week 12 (9.3 ± 30.39) significantly decreased and showed a pronounced improvement. The IBS-QOL total scores at week 4 and week 12 gradually decreased compared with that at the baseline and the QOL significantly improved. Treatment satisfaction rate was 79.3% in week 4 and 100% in week 12, showing a gradually increased satisfaction and significant differences. However, 11 cases (11.3%) had diarrhoea. Conclusion: Linaclotide has proved to be a safe and effective drug to improve IBS-C symptoms and severity.

The Effects of Combined Use of Linaclotide and Polyethylene Glycol Electrolyte Powder in Colonoscopy Preparation for Patients With Chronic Constipation

“…19,20 At present, linaclotide is predominantly used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). 21,22 Therefore, in this study, linaclotide was used to enhance the quality of the bowel preparation. Recent studies have demonstrated that the combination of linaclotide and PEG is an excellent and potentially effective bowel preparation regimen.…”

“…In contrast, it inhibits the activity of pain-sensing nerves and reduces intestinal discomfort 19,20 . At present, linaclotide is predominantly used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) 21,22 . Therefore, in this study, linaclotide was used to enhance the quality of the bowel preparation.…”

Decoding signaling mechanisms: unraveling the targets of guanylate cyclase agonists in cardiovascular and digestive diseases

“…Diarrhea occurred in 11 cases (11.3%). IBS-C symptoms and severity were improved with linaclotide, and the drug was safe and effective ( Liu et al, 2022 ). Another phase III clinical trial involving 659 Chinese IBS-C patients also showed that linaclotide (290 µg/day) was effective and well tolerated in Chinese IBS-C patients with rapid onset of action (NCT01880424) ( Peng et al, 2022 ).…”